Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 7/20 | 0.54 |
| ▸ | WNT3A | P56704 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979927 | 0.85 | CTNNB1 (0.56) | CTNNB1WNT3AKMT2ARAB9ANPC1 | |
| SCHEMBL15980124 | 0.83 | CTNNB1 (0.60) | CTNNB1WNT3AKMT2ARAB9ANPC1 | |
| SCHEMBL5378003 | 0.83 | CTNNB1 (0.63) | CTNNB1WNT3AKMT2ARAB9AHDAC6 | |
| SCHEMBL3790265 | 0.83 | CTNNB1 (0.56) | CTNNB1WNT3AKMT2ARAB9AHDAC6 | |
| SCHEMBL15969052 | 0.82 | CTNNB1 (0.56) | CTNNB1WNT3AKMT2ARAB9ANPC1 | |
| SCHEMBL15969237 | 0.82 | CTNNB1 (0.79) | CTNNB1WNT3ARAB9AHDAC6HTT | |
| SCHEMBL15979919 | 0.81 | CTNNB1 (0.60) | CTNNB1WNT3AKMT2ARAB9ANPC1 | |
| SCHEMBL15979985 | 0.81 | CTNNB1 (0.60) | CTNNB1WNT3AKMT2ARAB9AHDAC6 | |
| SCHEMBL15979951 | 0.80 | CTNNB1 (0.65) | CTNNB1WNT3AKMT2ANPC1POLB | |
| SCHEMBL15980123 | 0.80 | CTNNB1 (0.60) | CTNNB1WNT3AKMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| EP-1228060-A1 | ARYLALKANE, ARYLALKENE AND ARYL AZAALKANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032649-A1 | ARYLALKANE, ARYLALKENE AND ARYL AZAALKANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | CTNNB1 1453/4885WNT3A 2227/4885KMT2A 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.